Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.
Tumor-treating fields (TTFields) is a novel antimitotic treatment modality for patients with glioblastoma. To assess response to TTFields, a newly diagnosed patient with glioblastoma underwent diffusion, perfusion and 3D echo-planar spectroscopic imaging prior to initiation of TTFields plus temozolamide (baseline) and at 1- and 2-month follow-up periods. Increased mean diffusivity along with decreased fractional anisotropy and maximum relative cerebral blood volume were noted at 2 months relative to baseline suggesting inhibition of tumor growth and angiogenesis. Additionally, a reduction in choline/creatine was also noted during this period. These preliminary data indicate the potential of physiologic and metabolic MRI in assessing early treatment response to TTFields in combination with temozolamide.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Thalamus
- Temozolomide
- Outcome Assessment, Health Care
- Middle Aged
- Magnetic Resonance Spectroscopy
- Magnetic Resonance Imaging
- Image Processing, Computer-Assisted
- Humans
- Glioblastoma
- Follow-Up Studies
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Thalamus
- Temozolomide
- Outcome Assessment, Health Care
- Middle Aged
- Magnetic Resonance Spectroscopy
- Magnetic Resonance Imaging
- Image Processing, Computer-Assisted
- Humans
- Glioblastoma
- Follow-Up Studies